Dysregulations in hepatic lipid synthesis are often associated with obesity and type 2 diabetes, and therefore a perfect understanding of the regulation of this metabolic pathway appears essential to identify potential therapeutic targets. Recently, the transcription factor ChREBP (carbohydrate-responsive element-binding protein) has emerged as a major mediator of glucose action on lipogenic gene expression and as a key determinant of lipid synthesis in vivo. Indeed, liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in obese ob/ob mice. Since ChREBP cellular localization is a determinant of its functional activity, a better knowledge of the mechanisms involved in regulating its nucleo-cytoplasmic shuttling and/or its post-translational activation is crucial in both physiology and physiopathology. Here, we review some of the studies that have begun to elucidate the regulation and function of this key transcription factor in liver.

中文翻译：

---

ChREBP，葡萄糖和脂质代谢的转录调节因子。

肝脂质合成中的失调通常与肥胖症和2型糖尿病有关，因此，对这种代谢途径的调控的透彻了解对于鉴定潜在的治疗靶点显得至关重要。近年来，转录因子ChREBP（碳水化合物反应性元素结合蛋白）已成为葡萄糖对脂肪生成基因表达的主要介质，并且是体内脂质合成的关键决定因素。确实，肝脏特异性抑制ChREBP可改善肥胖ob / ob小鼠的肝脂肪变性和胰岛素抵抗。由于ChREBP细胞定位是其功能活性的决定因素，因此更好地了解参与调节其核质穿梭和/或其翻译后活化的机制对于生理学和生理病理学都是至关重要的。这里，